Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550696 | 0.90 | KMT2A (0.61) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL27810749 | 0.90 | NPC1 (0.53) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL11960979 | 0.88 | NPC1 (0.51) | KMT2AMEN1NPC1RAB9A | |
| SCHEMBL28751907 | 0.86 | KMT2A (0.59) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL28751873 | 0.84 | KMT2A (0.56) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL22981602 | 0.83 | KMT2A (0.55) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL18132139 | 0.81 | KMT2A (0.53) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL3494458 | 0.80 | KMT2A (0.52) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL28751905 | 0.80 | KMT2A (0.51) | KMT2AMEN1NPC1RAB9AKDM4E | |
| SCHEMBL1467919 | 0.80 | MEN1 (0.50) | KMT2AMEN1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873698-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873698-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2173750-B9 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORP (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160280708-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280708-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280708-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | INCYTE CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9371323-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371323-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371323-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE HOLDINGS CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2918586-A1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | Incyte Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2540723-A1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | Incyte Corporation (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8278318-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278318-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278318-B2 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | INCYTE CORPORATION (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2173750-B1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORP (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2173750-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | Incyte Corporation (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20080318991-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318991-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318991-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157752-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | INCYTE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280708-A1 | Spirocycles as Inhibitors of 11-beta Hydroxyl Steroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | KMT2A 3383/4885MEN1 2047/4885NPC1 364/4885 |
| US-20080318991-A1 | SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | KMT2A 3383/4885MEN1 2047/4885NPC1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.